WebBone marrow microenvironment in multiple myeloma progression. Substantial advances have been made in understanding the biology of multiple myeloma (MM) through … WebThe BM microenvironment is composed of a cellular compartment (stromal cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a non-cellular …
The role of the bone marrow microenvironment in multiple myeloma
Web14 apr. 2024 · Abstract. Background: The introduction of novel targeted therapies and immunotherapies has dramatically improved responses and overall survival in multiple myeloma (MM) patients. However, greater than 50% MM achieve refractory or relapse (r/r) within five-year due to MM target heterogeneity and bone marrow tumor … Web28 mar. 2024 · Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow and is characterized by the clonal proliferation of B-cells producing defective monoclonal immunoglobulins. Despite the latest developments in treatment, drug resistance remains one of the major challenges in the therapy of MM. … iho cat a surveyor
Engineered nanomedicine for myeloma and bone microenvironment ... - PNAS
Web27 iun. 2014 · CAFs in Multiple Myeloma. Multiple Myeloma (MM) is an incurable hematological malignancy characterized by the abnormal growth of malignant monoclonal plasma cells in the bone marrow. Clinical features of this disease include anemia, bone pain, renal failure, frequent occurrence of infections and hypercalcaemia. Web9 apr. 2024 · The C-X-C chemokine receptor type 4 (CXCR4) is a pleiotropic chemokine receptor that is expressed in not only normal hematopoietic cells but also multiple myeloma cells. Its ligand, stromal cell-derived factor 1α (SDF-1α) is produced in the bone marrow microenvironment. WebMultiple myeloma is rarely curable and its interactions with the bone marrow microenvironment are evident. However, separating cause from effect remains a … is there a aaa therom